公司資料
CorMedix Inc. 股價、新聞與催化劑
- 股票代碼:
- CRMD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.67 USD (+1.72%)
收盤價
最後更新: 2026年8月17日
641M USD
市值
股價為何變動
As of Aug 17, 2026, CRMD closed up 1.72% at $7.67. No new same-company headline was identified in the current news window.
公司概覽
Institutional Anti-Infective Company
CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
DefenCath
DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. It is the company’s largest commercial product.
Acquired Melinta Portfolio
The Melinta acquisition added marketed anti-infectives, including REZZAYO, and expanded CorMedix’s hospital-focused commercial organization.
Late-Stage Expansion Programs
CorMedix is developing REZZAYO for prophylaxis of invasive fungal disease after allogeneic stem-cell transplantation and DefenCath for patients receiving total parenteral nutrition.
未來催化劑
- Submission of an sNDA for REZZAYO prophylaxis in the third quarter of 2026.
- Potential FDA action on the REZZAYO sNDA in the first half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。